ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 293

False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign

Elisa Fernández1, Irene Monjo 2, Gema Bonilla 3, Chamaida Plasencia 4, Maria-Eugenia Miranda-Carus 2, Alejandro Balsa 4 and Eugenio de Miguel 5, 1Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, 2FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, 3Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, 4Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, 5Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Doppler ultrasound, giant cell arteritis, large vessel vasculitis, temporal arteritis and systemic vasculitides

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Imaging Of Rheumatic Diseases Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. The halo sign is an accepted valid test for the diagnosis of GCA in trained units. However, other conditions can also produce a hypoechoic increase of the arterial wall thickness and mimic the halo sign. Our aim was to describe the frequency and causes of false positives in the diagnosis of GCA by color Doppler ultrasound (CDUS).

Methods: We performed an observational retrospective study of 305 patients with temporal artery CDUS findings compatible with GCA. Their medical records were reviewed to collect demographic, physical examination, clinical and analytical data. The medical diagnosis based on the clinical evolution of the patient during at least 1 year of follow-up was established as the gold standard for definitive diagnosis.

Results: 14 of the 305 included cases (4.6%) were false positives. The characteristics of these 14 patients and their final diagnoses are shown in table 1. 64% were female. The median age was 72 (interquartile range 68-79) years. The median erythrocyte sedimentation rate was 55 (32-110) mm/h, C-reactive protein 15.1 (7.3-100.9) mg/L and hemoglobin 13.3 (11.2-14.1) g/dL. Five patients (36%) fulfilled the 1990 American College of Rheumatology classification criteria. A temporal artery biopsy was performed in 9 patients (64%), with negative results in all of them. Twelve patients (86%) had CDUS involvement of the superficial temporal arteries. Five had 1 branch involved (42%), three 2 branches (25%), two 3 branches (17%) and two 4 branches (17%). In addition, two patients (14%) had an isolated halo sign in the axillary arteries, one unilateral and the other bilateral. Regarding the definitive diagnosis, in four patients it was polymyalgia rheumatica (29%), in three atherosclerosis (21%), and there was one case each of non-Hodgkin’s Lymphoma type T, osteomyelitis of the skull base, primary amyloidosis associated with multiple myeloma, granulomatosis with polyangiitis, neurosyphilis, urinary sepsis and narrow-angle glaucoma.

Conclusion: CDUS diagnosis of GCA yields a low percentage of false positives. These are attributable either to operator-dependent technical mistakes or to the presence of other medical conditions that alter the US signal of the arterial wall, resulting in a halo sign. The clinician must be aware of the existence of these conditions when interpreting this test, in order to improve the diagnostic accuracy of the CDUS.


Table 1


Disclosure: E. Fernández, None; I. Monjo, BMS, 2; G. Bonilla, None; C. Plasencia, None; M. Miranda-Carus, BMS, 2, Roche Pharma, 2; A. Balsa, BMS, 2, Roche Pharma, 2; E. de Miguel, AbbVie, 2, 5, 8, BMS, 8, BMS, MSD, UCB, Roche, 8, MSD, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 8, UCB, 8.

To cite this abstract in AMA style:

Fernández E, Monjo I, Bonilla G, Plasencia C, Miranda-Carus M, Balsa A, de Miguel E. False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/false-positives-in-the-ultrasound-diagnosis-of-giant-cell-arteritis-some-diseases-can-also-have-halo-sign/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/false-positives-in-the-ultrasound-diagnosis-of-giant-cell-arteritis-some-diseases-can-also-have-halo-sign/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology